A phase I trial of concurrent chemoradiotherapy with non-split administration of docetaxel and cisplatin for dry stage III non-small-cell lung cancer
Cancer Chemotherapy and Pharmacology,  Clinical Article

Hida N et al. – Concurrent chemoradiotherapy (cCRT) with non–split docetaxel (D) plus cisplatin (P) was a tolerable and effective regimen, and recommended dose (RD) was 50/80mg/m2 every 4weeks.

  • Patients (aged ≤70years) with unresectable dry stage III non-small-cell lung cancer (NSCLC) and having performance status 0 or 1 and adequate organ function were eligible.
  • They received radiotherapy (60 Gy in 30 fractions) once daily starting on day 2.
  • Concurrent P (day 1; 60mg/m2 at Levels 1–3, 80mg/m2 at Level 4) and D (day 1; 30mg/m2 at Level 1, 40mg/m2 at Level 2, 50mg/m2 at Levels 3–4) were administered every 4weeks for 2–4 courses.

  • Eighteen patients were enrolled (stage IIIA/IIIB, 5/13 patients).
  • Three cases of dose-limiting toxicity were observed in this study, although another 3 cases were added at Levels 2 and 3.
  • Radiotherapy was completed in 15 patients.
  • Seventeen patients received more than 2 courses of chemotherapy.
  • Neither Grade 3/4 esophagitis nor severe hematological events were observed at Levels 1–4.
  • However, dose escalation to Level 5 (P [80mg/m2], D [60mg/m2]) was stopped because the Level 5 dose was the recommended dose (RD) of chemotherapy alone for stage IIIB/IV NSCLC in Japan.
  • Therefore, the RD was determined as D50/P80mg/m2 in this cCRT.
  • The objective response rate was 89 %, and the median survival time was 23.6months.

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Oncology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Oncology Articles

1 Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA) Journal of Clinical Oncology, May 29, 2014    Clinical Article

2 Relevance of gamma knife radiosurgery alone for the treatment of non-small cell lung cancer brain metastases Clinical Neurology and Neurosurgery, August 22, 2014    Clinical Article

3 B7-H1/PD-1 blockade therapy in non–small cell lung cancer: current status and future direction Full Text The Cancer Journal, August 13, 2014    Free full text    Review Article

4 Fish consumption and lung cancer risk: systematic review and meta-analysis Nutrition and Cancer, April 21, 2014    Evidence Based Medicine    Review Article

5 Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer: An analysis of Veterans Health Administration data Journal of Thoracic Oncology, April 25, 2014    Clinical Article

6 Does the method of radiologic surveillance impact survival following resection of stage I non-small cell lung cancer? The Journal of Thoracic and Cardiovascular Surgery, August 21, 2014    Clinical Article

7 EGFR blockade enriches for lung cancer stem-like cells through Notch3-dependent signaling Cancer Research, August 29, 2014    Clinical Article

8 Lung cancer: Is surgery an option for persisting N2 after induction therapy? Zentralblatt für Chirurgie - Zeitschrift für Allgemeine, Viszeral-, Thorax- und Gefäßchirurgie, August 18, 2014    Clinical Article

9 Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium International Journal of Cancer, June 23, 2014    Clinical Article

10 Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial The Lancet, June 4, 2014    Evidence Based Medicine    Clinical Article

11 Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial The Lancet Oncology, January 24, 2014    Clinical Article

12 Clinical genotyping and efficacy outcomes: exploratory biomarker data from the phase II ABIGAIL study of first-line bevacizumab plus chemotherapy in non-squamous non-small-cell lung cancer Lung Cancer, August 19, 2014    Clinical Article

13 Metastatic sites and survival in lung cancer Lung Cancer, August 11, 2014    Clinical Article

14 A review of the management of elderly patients with non–small-cell lung cancer Annals of Oncology, August 4, 2014    Review Article

15 A retrospective comparison of adjuvant chemotherapeutic regimens for non-small cell lung cancer (NSCLC): Paclitaxel plus carboplatin versus vinorelbine plus cisplatin Lung Cancer, February 14, 2014    Clinical Article

16 The impact of diagnostic imaging wait times on the prognosis of lung cancer Canadian Association of Radiologists Journal , August 1, 2014    Clinical Article

17 Ninety-day mortality after resection for lung cancer is nearly double 30-day mortality The Journal of Thoracic and Cardiovascular Surgery, August 20, 2014    Clinical Article

18 Ceritinib in ALK-rearranged non-small-cell lung cancer New England Journal of Medicine, March 31, 2014    Evidence Based Medicine    Clinical Article

19 Retrospective evaluation of thromboembolic events in patients with non-small cell lung cancer treated with platinum-based chemotherapy Lung Cancer, August 11, 2014    Clinical Article

20 Phase II study of stereotactic body radiotherapy to primary tumor and metastatic locations in oligometastatic non-small cell lung cancer patients Annals of Oncology, August 26, 2014    Clinical Article

Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More